Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma

Annals of Thoracic and Cardiovascular Surgery

Volumn 18, Issue 6, 2012, Pages 506-513

  Kono, Koji ^a,b   Mimura, Kousaku ^a   Fujii, Hideki ^c   Shabbir, Asim ^a   Yong, Wei Peng ^a   So, Jimmy ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Cetuximab; EGFR; Esophageal squamous cell carcinoma; HER2; Herceptin

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; ERLOTINIB; GEFITINIB; LAPATINIB; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG DELIVERY SYSTEM; ESOPHAGUS TUMOR; GENETICS; HUMAN; PROTO ONCOGENE; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; ESOPHAGEAL NEOPLASMS; GENES, ERBB-1; GENES, ERBB-2; HUMANS; QUINAZOLINES;

EID: 84871691104     PISSN: 13411098     EISSN: 21861005     Source Type: Journal    
DOI: 10.5761/atcs.ra.12.01995     Document Type: Review

References (65)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
2. Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-72; discussion 372-3.
3. Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-32.
4. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a japan clinical oncology Group Study-JCOG9204. J Clin Oncol 2003; 21: 4592-6.
5. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702.
6. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-55.
7. Levkowitz G, Klapper LN, Tzahar E, et al. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF- receptor but not to other ErbB proteins. Oncogene 1996; 12: 1117-25.
8. Kimura M, Tsuda H, Morita D, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004; 445: 255-62.
9. Ghaderi A, Vasei M, Maleck-Hosseini SA, et al. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 2002; 8: 252-6.
10. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895-904.
11. DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 23: 1152-60.
12. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
13. Di Lorenzo G, Tortora G, D'Armiento F P, et al.Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgenindependence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44.
14. Wester K, Sjöström A, de la Torre M, et al. HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002; 41: 282-8.
15. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology (Williston Park). 2001; 61(Suppl 2): 1-13.
16. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80.
17. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994; 74: 795-804.
18. Yano H, Shiozaki H, Kobayashi K, et al. Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer 1991; 67: 91-8.
19. Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92: 1253-60.
20. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-7.
21. Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab-and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007; 97: 494-501.
22. Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131: 111-9.
23. Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology (Williston Park). 2002; 63 (Suppl 1): 17-24.
24. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14: 922-30.
25. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-7.
26. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006; 12(14 Pt 1): 4283-7.
27. Bonner JA, De Los Santos J, Waksal HW, et al. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol. 2002; 12(3 Suppl 2): 11-20.
28. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29(1 Suppl 4): 27-36.
29. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 2002; 11: 837-49.
30. Waxman ES, Herbst RS. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Semin Oncol Nurs 2002; 18(2 Suppl 2): 20-9.
31. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002; 14: 334-42.
32. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl 4): S3-8.
33. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12(Suppl 1): S3-8.
34. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
35. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev [Review]. 2010; 36: 235-48.
36. Sutter AP, Höpfner M, Huether A, et al. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006; 118: 1814-22.
37. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312: 1175-8.
38. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-9.
39. Maruyama T, Mimura K, Izawa S, et al. Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression. Anticancer Res 2011; 31: 2999-3005.
40. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28: 803-14.
41. Mimura K, Kono K, Maruyama T, et al. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer 2011; 129: 2408-16.
42. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
43. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26: 1066-72.
44. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26 (4 Suppl 12): 60-70.
45. Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61: 4892-900.
46. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.
47. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-96.
48. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-8.
49. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 4898-904.
50. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008; 70: 391-5.
51. Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29: 626-31.
52. De Vita F, Orditura M, Martinelli E, et al. A multi-center phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011; 104: 427-32.
53. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5- fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the arbeitsgemeinschaft internistische onkologie. Ann Oncol 2009; 20: 1667-73.
54. Schønnemann KR, Yilmaz M, Bjerregaard JK, et al. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer 2012; 48: 510-7.
55. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-7.
56. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
57. Real PJ, Benito A, Cuevas J, et al. Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. Cancer Res 2005; 65: 8151-7.
58. Wild R, Fager K, Flefleh C, et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 2006; 5: 104-13.
59. Watanabe M, Kono K, Kawaguchi Y, et al. NK cell dysfunction with down-regulated CD16 and upregulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus 2010; 23: 675-81.
60. Izawa S, Kono K, Mimura K, et al. HO production within tumor microenvironment inversely correlated with infiltration of CD56 (dim) NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. Cancer Immunol Immunother 2011; 60: 1801-10.
61. Watanabe M, Kono K, Kawaguchi Y, et al. Interleukin- 21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 2010; 102: 520-9.
62. Eriksen KW, Søndergaard H, Woetmann A, et al. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol Immunol 2009; 46: 812-20.
63. Daly JM, Weintraub FN, Shou J, et al. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995; 221: 327-38.
64. Maruyama T, Mimura K, Izawa S, et al. Immunonutritional diet modulates natural killer cell activation and Th17 cell distribution in patients with gastric and esophageal cancer. Nutrition 2011; 27: 146-52.
65. Kaur A, Dasanu CA. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert Opin Pharmacother 2011; 12: 2493-503.